Support Alert

Drug Safety Update: Brimonidine gel (Mirvaso): risk of exacerbation of rosacea

09 Nov 2016

The Medicines and Healthcare products Regulatory Agency (MHRA) have produced a drug safety update for the use of Brimonidine (Mirvaso) to highlight that symptom exacerbation has been reported very commonly in patients treated with brimonidine gel. 

For further information about the risks and advice for healthcare professionals see the Drug Safety Update